Group 1 - The innovative drug sector has shown strong performance since September 24, 2024, ending a four-year adjustment period and resuming an upward trend [1] - In the second quarter, large-scale external licensing deals and ongoing domestic policy support have led to a revaluation of innovative drug companies [1] - The stock performance of the innovative drug industry has positively impacted upstream and CXO companies, with some companies already seeing improved performance in 2025 [1] Group 2 - The innovative drug industry historically performs well in low-interest-rate environments, but this is not the sole factor for its strength [2] - The financing environment for U.S. biopharmaceutical companies has been challenging due to high interest rates and negative policies, but improvements are expected in the second half of the year [2] - The Hong Kong market currently offers a more favorable financing environment for innovative drug companies, with many companies recently listing there [2]
博时基金陈西铭：看好下半年创新药板块行情
Zhong Guo Jing Ji Wang·2025-08-11 08:50